Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Maspin
is a protein that belongs to serin protease inhibitor (serpin) superfamily. The purpose of this study was to review the literature concerning the expression of maspin in salivary gland tumours. A literature search was done using MEDLINE, accessed via the National Library of Medicine PubMed interface. Statistical analysis was not done because only seven studies were available in literature, the collected data were different and the results could not be compared. Expression of maspin was down regulated in more aggressive salivary gland tumours.
Maspin
may function as a
tumour suppressor
in salivary gland tumours.
...
PMID:Maspin as a tumour suppressor in salivary gland tumour. 2565 53
Aberrant gene expression is a hallmark of cancer. Although transcription is traditionally considered 'undruggable', the development of CRISPR-associated protein 9 (Cas9) systems offers enormous potential to rectify cancer-associated transcriptional abnormalities in malignant cells. However delivery of this technology presents a critical challenge to overcome in order to realize clinical translation for cancer therapy. In this article we demonstrate for the first time, a fully synthetic strategy to enable CRISPR-mediated activation (CRISPRa) of
tumour suppressor
genes
in vivo
using a targeted intravenous approach. We show this
via
highly efficient transcriptional activation of two model
tumour suppressor
genes, Mammary Serine Protease Inhibitor (
MASPIN
,
SERPINB5
) and cysteine-rich 61/connective tissue growth factor/nephroblastoma-overexpressed 6 (
CCN6
,
WISP3
), in a mouse model of breast cancer. In particular, we demonstrate that targeted intravenous delivery of can be achieved using a novel nanoscale dendritic macromolecular delivery agent, with negligible toxicity and long lasting therapeutic effects, outlining a targeted effective formulation with potential to treat aggressive malignancies.
...
PMID:Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. 3158 20
<< Previous
1
2